Geneos Wealth Management’s Galectin Therapeutics GALT Stock Holding History

Geneos Wealth Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.12M	Sell	240,427 -500	-0.2%	-$1.3K	0.02%	518
2026 Q1	$672K	Sell	240,927 -2,400	-1%	-$7.3K	0.02%	607
2025 Q4	$1.01M	Sell	243,327 -116,848	-32%	-$615K	0.02%	501
2025 Q3	$1.53M	Sell	360,175 -63,060	-15%	-$237K	0.04%	401
2025 Q2	$893K	Sell	423,235 -427,435	-50%	-$639K	0.02%	562
2025 Q1	$1.04M	Buy	850,670 +461,735	+119%	+$648K	0.01%	652
2024 Q4	$502K	Buy	388,935 +36,000	+10%	+$86.3K	0.02%	589
2024 Q3	$971K	Sell	352,935 -40,790	-10%	-$100K	0.04%	413
2024 Q2	$890K	Sell	393,725 -15,125	-4%	-$45.9K	0.04%	383
2024 Q1	$977K	Sell	408,850 -3,800	-0.9%	-$7.19K	0.04%	355
2023 Q4	$685K	Sell	412,650 -4,700	-1%	-$9.12K	0.03%	405
2023 Q3	$801K	Sell	417,350 -4,300	-1%	-$7.07K	0.04%	356
2023 Q2	$607K	Sell	421,650 -5,750	-1%	-$9.75K	0.03%	429
2023 Q1	$898K	Sell	427,400 -7,400	-2%	-$11.9K	0.05%	313
2022 Q4	$491K	Sell	434,800 -10,400	-2%	-$13.9K	0.03%	427
2022 Q3	$725K	Sell	445,200 -32,867	-7%	-$61.4K	0.05%	313
2022 Q2	$626K	Buy	478,067 +3,300	+0.7%	+$4.74K	0.03%	438
2022 Q1	$764K	Sell	474,767 -6,000	-1%	-$11.6K	0.03%	432
2021 Q4	$995K	Sell	480,767 -10,600	-2%	-$30.3K	0.04%	397
2021 Q3	$1.87M	Sell	491,367 -900	-0.2%	-$3.05K	0.07%	257
2021 Q2	$1.56M	Sell	492,267 -19,339	-4%	-$68.8K	0.06%	274
2021 Q1	$2.26M	Buy	511,606 +26,000	+5%	+$58.3K	0.06%	272
2020 Q4	$961K	Buy	485,606 +448,589	+1,212%	+$1.18M	0.04%	357
2020 Q3	$101K	Hold	37,017	–	–	0.01%	938
2020 Q2	$108K	Sell	37,017 -4,733	-11%	-$11.9K	0.01%	887
2020 Q1	$80K	Sell	41,750 -2,000	-5%	-$4.87K	0.01%	918
2019 Q4	$126K	Sell	43,750 -400	-0.9%	-$1.39K	0.01%	863
2019 Q3	$160K	Sell	44,150 -9,000	-17%	-$32.5K	0.01%	725
2019 Q2	$220K	Sell	53,150 -2,500	-4%	-$10.8K	0.01%	636
2019 Q1	$284K	Sell	55,650 -4,000	-7%	-$19.2K	0.02%	547
2018 Q4	$224K	Hold	59,650	–	–	0.02%	564
2018 Q3	$358K	Buy	59,650 +47,300	+383%	+$260K	0.02%	465
2018 Q2	$78K	Sell	12,350 -29,040	-70%	-$141K	0.01%	870
2018 Q1	$196K	Sell	41,390 -32,095	-44%	-$150K	0.02%	546
2017 Q4	$245K	Buy	73,485 +4,873	+7%	+$12.3K	0.02%	482
2017 Q3	$146K	Buy	68,612 +8,000	+13%	+$15.9K	0.01%	602
2017 Q2	$149K	Buy	60,612 +4,000	+7%	+$10.7K	0.02%	573
2017 Q1	$130K	Buy	56,612 +4,000	+8%	+$6.03K	0.01%	589
2016 Q4	$51K	Buy	52,612 +1,800	+4%	+$1.6K	0.01%	833
2016 Q3	$57K	Hold	50,812	–	–	0.01%	766
2016 Q2	$77K	Hold	50,812	–	–	0.01%	665
2016 Q1	$73K	Buy	+50,812	New	+$68.2K	0.01%	673

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Geneos Wealth Management's GALT Position: Q2 2026 in Review

Geneos Wealth Management reduced its Galectin Therapeutics (GALT) stake by 0.21% in Q2 2026, selling an estimated $1.3K and leaving 240,427 shares worth $1.12M. The position accounts for 0.02% of the portfolio, ranked #518.

Geneos Wealth Management first reported a position in GALT in Q1 2016 and has held it in 42 quarters since. The position peaked at $2.26M in Q1 2021. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

Geneos Wealth Management held 240,427 shares of Galectin Therapeutics worth $1.12M as of Q2 2026.
Geneos Wealth Management sold 500 Galectin Therapeutics shares in Q2 2026, an estimated $1.3K.
Galectin Therapeutics made up 0.02% of Geneos Wealth Management's portfolio in Q2 2026, its #518 holding.
Geneos Wealth Management first reported a position in Galectin Therapeutics in Q1 2016 and has held it in 42 quarters since.
Geneos Wealth Management's Galectin Therapeutics position peaked at $2.26M in Q1 2021.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.